People
Yancopoulos, Regeneron’s founder and chief scientific officer, and Schleifer, chief executive officer, argue in the article that while drug affordability is important, the single-minded argument detracts from “the overwhelming health care crisis facing our society” and creates a negative image of an industry that provides substantial benefit to society.
Mark Emalfarb, founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International, believes he knows how to revolutionize biopharma manufacturing. Emalfarb took time out to talk to BioSpace about his company and its C1 technology platform.
Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
Israel-based Teva Pharmaceutical’s second-quarter financial report led off with a dramatic 18 percent drop in quarterly revenue compared to the same period the year before. The company reported second-quarter sales of $4.7 billion.
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
Oncorus, a biotechnology company based in Cambridge, Massachusetts, announced that Theodore (Ted) T. Ashburn had been chosen as the company’s new president and chief executive officer.
It’s pretty easy to complain about the price of drugs. Drug companies typically spend billions of dollars to develop a drug, and often spend billions of dollars to develop drugs that never get approved. But a surprising critic of the U.S. system of pricing drugs is Leonard Schleifer.
Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
PRESS RELEASES